202196-97-2

Basic information

• Product Name: (1-Benzyl-1H-indazol-5-yl)-(6-(5-methanesulphonylmethyl-1,2,4-oxadiazol-3-yl)-quinazolin-4-yl)-amine
• CAS NO: 202196-97-2
• Molecular Weight: 511.564
• Mol File: 202196-97-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1-Benzyl-1H-indazol-5-yl)-(6-(5-methanesulphonylmethyl-1,2,4-oxadiazol-3-yl)-quinazolin-4-yl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Benzyl-1H-indazol-5-yl)-(6-(5-methanesulphonylmethyl-1,2,4-oxadiazol-3-yl)-quinazolin-4-yl)-amine(202196-97-2)
• EPA Substance Registry System: (1-Benzyl-1H-indazol-5-yl)-(6-(5-methanesulphonylmethyl-1,2,4-oxadiazol-3-yl)-quinazolin-4-yl)-amine(202196-97-2)

Safety Data

• Hazardous Substances Data: 202196-97-2(Hazardous Substances Data)

Upstream product

• 4455-15-6 ethyl methanesulfonylacetate 

Relevant articles and documents

Fused heterocyclic compounds as protein tyrosine kinase inhibitors

Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH2), (CH2)W, or W, in which W is O, S(O)mwherein m is 0, 1 or 2, or NRawherein Rais hydrogen or a C1-8alkyl group; R1represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O)m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O)matoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R1being optionally substituted by one or more R3;groups; P=0 to 3; U, R2, R3are as defined in the application.